A Safety Study of NNZ-2566 in Patients With Fragile X Syndrome

NCT01894958 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

72

Enrollment

INDUSTRY

Sponsor class

Conditions

Fragile X Syndrome

Interventions

DRUG: NNZ-2566
DRUG: Placebo

Sponsor

Neuren Pharmaceuticals Limited